TrialThe Journal of dermatology2025

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial.

Jianzhong Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.